Altamont Capital-backed Amplity Health, a global medical and commercial partner to biopharmaceutical companies, agreed to merge with The Lynx Group, a medical communications company specializing in oncology and complex drugs. Financial terms were not disclosed. “Medical and commercial strategies for our biopharmaceutical clients have become highly specialized, and the new entry point for commercial conversations is when clinical, medical, and specialist professionals are framing the scientific narrative and the payer/patient value proposition. Lynx engages with a unique combination of oncology and complex drug experts to create proprietary medical communications, produce topical and relevant events with their association partners, and develop high-quality scientific messages and publications that shape drug development and launch. In the past 3 years alone, Lynx has participated in 80% of all successful oncology brand launches," Michael A. Griffith, Amplity President and CEO.